Using a 4-hydroxytamoxifen (4OHT)-inducible, conditional Sos1-null mutation, we analyzed wild-type (WT), single Sos1-KO, Sos2-KO and double Sos1/2 KO primary mouse embryonic fibroblasts (MEF) with an ...
Signal transduction by GRB2 and SOS1. When some substances bind to a membrane receptor, a reaction occurs between the receptor and GRB2, which then goes on to bind and activate SOS1. SOS1 can then ...
Researchers from Tokyo Metropolitan University have uncovered new insights into how the proteins GRB2 and SOS1 in cells pass signals from membrane receptors to nuclei. They used nuclear magnetic ...
Activation of the small G protein Ras is required for thymocyte differentiation. In thymocytes, Ras is activated by the Ras guanine exchange factors (RasGEFs) Sos1, Sos2, and RasGRP1. We report the ...
Activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) underlie the pathogenesis and chemoresistance of ∼30% of all human tumors, yet the development of high-affinity inhibitors ...
BAY3498264 is an investigational oral selective SOS1 inhibitor with potential to treat a variety of KRAS-mutated cancers, such as non-small cell lung cancer, pancreatic cancer and colorectal cancer ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced ...
Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor (GEF) in KRAS-driven tumors, and it also functions as a downstream node protein of BCR-ABL, suggesting its critical ...
A previously healthy infant who suffered aborted sudden cardiac death was found to have a de novo genetic mutation in the SOS1 gene. Such mutations are typical of Noonan syndrome and suggests the ...
Son of sevenless 1 (SOS1) is a guanine exchange factor (GEF) primarily responsible for linking cell-surface receptors to RAS protein activation converting the inactive form of GDP-loaded RAS proteins ...
Bayer announced initiation of a phase I clinical trial with BAY3498264, an investigational oral selective Son of Sevenless Homologue 1 (SOS1) inhibitor. The open-label, first-in-human, dose escalation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback